Vimarsana
Biggest News Aggregation in the World

Page 7 - Sofinnova Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sofinnova Partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sofinnova Partners Today - Breaking & Trending Today

Singapore's M&L Healthcare sells new diabetes-related treatment to Nasdaq firm for $334 million - Vimarsana News

Singapore's M&L Healthcare sells new diabetes-related treatment to Nasdaq firm for $334 million

M&L Healthcare is a family-owned investment fund founded by shipping tycoon Michael Kum and his wife Lynda. Read more at straitstimes.com.

Asia Digest: M&L Healthcare sells LimFlow; NTT Docomo joins Mitsui-led group to bid for Edotco - Vimarsana News

Asia Digest: M&L Healthcare sells LimFlow; NTT Docomo joins Mitsui-led group to bid for Edotco

LimFlow will receive $250 million in cash and be eligible to receive up to $165 million in additional payments.

GenSight: Sofinnova Partners exceeds 20% stake -November 27, 2023 at 08:57 am EST - Vimarsana News

GenSight: Sofinnova Partners exceeds 20% stake -November 27, 2023 at 08:57 am EST

Sofinnova Partners, acting on behalf of the Sofinnova Crossover I SLP fund, has declared to the AMF that on November 21 it exceeded the thresholds of 20% of the capital and voting rights in GenSight...

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics - Vimarsana News

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announce that they have entered into a license agreement under which Myricx will have exclusive

Source: yahoo.com
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors - Vimarsana News

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SIOUX FALLS, S.D., Nov. 20, 2023 -- SAB Biotherapeutics , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte...